



December 20, 2016

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2011-001884-39/ Novartis Protocol ID CBEZ235ZIC01

A phase II study of orally administered BEZ235 monotherapy in patients with metastatic or unresectable malignant PEComa

Trial CBEZ235ZIC01 was cancelled with no patient enrollment and as such, no results will be reported.